Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-867-5 | CAS number: 111-41-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
AEEA is rapidly and quantitatively absorbed following oral administration. A comparable inhalation absorption is assumed. Nonetheless, a default factor of 2 (ECHA REACH TG ) was applied for oral to inhalation extrapolation as a conservative approach. Dermal absorption is approx. 10%. Excretion is rapid and occurs predominantly via urine, as unchanged AEEA (55-65%) and to a lesser extent as metabolites (N-acetyl-AEEA (5-11%), two unidentified metaboites accounting for 16-30%).
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
2-(2-aminoethylamino)ethanol (AEEA) is rapidly and quantitatively (> 85 % within 48 hours) absorbed following oral administration to female Wistar rats (t½ values 0.1 -0.2 hours). Maximum blood levels were reached within 0.5 hours. The organ distribution was low and comparable in all experiments. No significant difference occurred with respect to dose level.
Excretion was also rapid with most of the dose (85 - 98 %) recovered in the 0 - 48 hour urine, less in feces and only very low quantities in expired volatiles and as 14CO2. The plasma elimination of orally administered 14C-AEEA was biphasic, with alpha and beta elimination t½ -values of 1.6 - 1.8 hours and 16.7 - 17.3 hours, respectively. Radioactivity at termination in tissues was low (2.3 -3.3 %). Only the parent compound AEEA was found in plasma. Most of AEEA was excreted unchanged in the urine. Four radiolabeled metabolites were observed in urine from all three oral dose groups. These metabolites comprised approximately 5 - 10 % (Metabolite A), 11 -20 % (Metabolite B), 5 - 11 % (N-acetyl-AEEA) and 55-65 % (AEEA) of the administered dose. The pregnancy status did not cause significant differences in absorption, elimination, excretion, and metabolic profile following the oral administration of AEEA.After 8 hour dermal application of a 10 -fold higher dose, no quantifiable plasma levels were reached at most readings. Urinary excretion was quantifiable, and bioavailability was approx. 10 % compared to the oral route. The amount of absorbed test material here was 8.44 +/- 6.1 %.
Absorption after inhaltion exposure is assumed to be comparable to oral absorption.
In a toxicokinetics study AEEA (14C-labeled) was administered to pregnant Wistar rats to examine the distribution of 14C-AEEA in conceptus tissues following repeated dose application. Three animals from 2 groups were orally administered 14C-AEEA (300 mg/kg, 470 uCi/kg) daily during GD 17 to 19, the fourth rat in each group was not treated, but was used to determine background radioactivity. All animals were anesthetized by isoflurane inhalation either 6 or 48 h after the third and final dose of 14C-AEEA. Dam blood was collected from the vena cava after caesarean section while under deep anesthesia. Following collection of the amniotic fluid and chorioallentoic placenta, the fetuses from each litter were divided into four subgroups of at least two fetuses each, for further evaluation: a) determination of the total radioactivity in fetal blood, aorta, and the remaining carcass, b) autoradiography of isolated vessels and c) autoradiography of vessels in situ.
AEEA-derived radioactivity (as 14C-AEEA equivalents) was fairly evenly partitioned between the fetal and maternal compartments 6 hr after the final dose was given on GD 19, such that the blood level in the fetus was about 80 % of that in the dam (36.2 and 47.0 ug-eq AEEA/g blood, respectively, p > 0.05). The level of 14C-AEEA equivalents fell in both compartments over the following 42 h (p < 0.05, compared to 6 h), but was still markedly present and more so in the fetus. At 48 h after the final dose, fetal and maternal blood levels were reduced to 67 and 25 % of the 6 -h values, that is 24.4 and 11.9 ug-eq AEEA/g blood, respectively (p < 0.05).
Within the fetus, radioactivity was distributed evenly between the aortic arch, descending aorta, and the remainder of the carcass at 6 h (p > 0.05), but appeared to be marginally retained in the aortic vessels compared to the carcass at 48 h (p < 0.05). Autoradiography of whole fetus and great vessels collected from fetuses at GD 19 (group 1, subgroups 2 and 3) showed radioactivity to be evenly distributed throughout the fetus, with a slightly higher concentration in the liver, consistent with absorption of radioactive material through the hepatic portal vein. There was no apparent preferential localization of radioactivity associated with the great vessels, either in situ or in isolated vessels. Upon macroscopic investigation of fetuses from subgroup 2, five of the six fetuses from group 2 that were examined on GD 21 exhibited high aortic arch. None of those from group 1 that were examined on GD 19 exhibited the lesion.
In a toxicokinetics study AEEA (14C-labeled) was administered to pregnant Wistar rats to examine the potential transfer of AEEA to the suckling pup at a known peri-postnatal developmentally toxic dose level following repeated dose application. Three animals from 2 groups were orally administered 14C-AEEA (250 -300 mg/kg bw) daily during PND 1 -12.
Approximately 6 hr after the administration of 14C-AEEA, milk (approximately 300 uL) was collected from group 1 animals on LD 4 and LD 12 and from group 2 animals on LD 8. Pups were separated from the dams 4 h before milking, and returned within 5 min after the collection of milk.
Approximately 5 min before milking, the dams were anesthetized with isoflurane and injected intraperitoneally with oxytocin (1–2 IU) in two split doses, 5 to 10 min apart. After the collection of milk, blood was collected from the pedal vein, jugular vein, or sinus orbital. Milk and blood samples were analyzed for radioactivity by liquid scintillation spectrometry.
Although the level of radioactivity in the blood of the dams was consistent over the 12-day exposure period, the concentration of AEEA fell after LD 5, reflecting a decrease in the delivered dose of AEEA as the specific activity of the dosing solution increased on LD 6. Animals that were milked on LD 4 had received 300 mg AEEA/kg bw before sample collection, whereas those milked at later time points received 240 mg AEEA/kg bw from LD 6. As a consequence, the level of 14C-AEEA equivalents in the blood fell and was 10 % lower on LD 8 compared to LD 4, but was essentially unchanged between LD 8 and LD 12. Orally administered 14C-AEEA equivalents partitioned preferentially into milk by 1.6- to 2.5-fold. The concentration of 14C-AEEA equivalents in the milk decreased by 10 % between LD 4 and LD 8, in line with the reduction in blood level, but fell by over 30 % during LD 8 to 12 (p = 0.0538). The potential exposure of the suckling offspring was calculated from the concentration of 14C-AEEA equivalents in the milk, along with assumptions for milk consumption and bodyweight of suckling Wistar rat pups. The derived values for pup bodyweights on LD 4, LD 8, and LD 12 were 10, 16, and 24 g, respectively, while for milk consumption they were 4.0, 5.3, and 6.0 g, respectively. Pup exposure to 14C-AEEA equivalents (AEEA and metabolic derivatives) was estimated to be 28.6, 21.1, and 10.8 mg/g on LD 4, LD 8, and LD 12, respectively, equivalent to 9.6, 8.8, and 4.5 % of the dose administered to the dams on the same day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.